Janux Therapeutics

Janux Therapeutics Advances JANX007 to Phase 1b Trials for Prostate Cancer with Promising Survival Data

20 days ago

• Janux Therapeutics has initiated Phase 1b expansion studies of JANX007 in taxane-naïve metastatic castration-resistant prostate cancer patients, marking progression to earlier treatment lines. • Updated data from Phase 1a trials showed median radiographic progression-free survival of 7.5 months across all patients, with improved outcomes of 7.9 months in higher-dose cohorts. • The company plans three additional Phase 1b studies exploring JANX007 as both monotherapy and in combination therapy, with further clinical updates expected in the second half of 2025.

FDA Grants Fast Track Status to NKGen's NK Cell Therapy Troculeucel for Moderate Alzheimer's Disease

3 months ago

• NKGen Biotech's innovative NK cell therapy troculeucel has received FDA Fast Track Designation for treating moderate Alzheimer's disease, potentially accelerating its development pathway. • Early clinical benefits were observed in Phase 1 trials of troculeucel, an ex vivo expanded autologous NK cell therapy, showing promise for moderate Alzheimer's patients. • The company is currently conducting Phase 2a trials, with updated clinical data expected by the end of 2025, addressing a critical need in the 30% of Alzheimer's cases classified as moderate.

Janux Data Boosts Confidence in Vir Biotechnology's Masked TCE Pipeline

6 months ago

• Morgan Stanley highlights Janux Therapeutics' positive Phase 1a data for JANX007 in metastatic castration-resistant prostate cancer. • The analyst suggests these findings provide a favorable readthrough for Vir Biotechnology's masked T-cell engager (TCE) pipeline. • Vir Biotechnology is anticipated to release initial Phase 1 monotherapy data from VIR-5818 and VIR-5500 in the first quarter of 2025. • Morgan Stanley maintains an Equal Weight rating on Vir shares, setting a price target of $10.

Janux Therapeutics' JANX007 Shows Promise in Advanced Prostate Cancer Trial

6 months ago

• Janux Therapeutics' JANX007 demonstrated significant PSA reduction in heavily pre-treated metastatic castration-resistant prostate cancer patients. • The Phase 1a study showed a favorable safety profile with mostly mild to moderate treatment-related side effects, including cytokine release syndrome. • Analysts are optimistic about JANX007's potential, citing its efficacy and safety profile, and have raised peak sales estimates. • Janux has selected doses for Phase 1b expansion trials in patients with less advanced disease who have not received Pluvicto, with updated results expected next year.

Janux Therapeutics' JANX007 Shows Promising Activity in Metastatic Castration-Resistant Prostate Cancer

6 months ago

• Janux Therapeutics' JANX007 demonstrated substantial clinical activity in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients. • In a Phase 1a trial, 100% of patients achieved best PSA50 declines, with 63% and 31% achieving PSA90 and PSA99 declines, respectively. • The PSMA-TRACTr JANX007 was well-tolerated, with cytokine release syndrome (CRS) and treatment-related adverse events (TRAEs) primarily limited to grades 1 and 2. • Based on these results, Janux has identified two dose regimens for Phase 1b expansion trials in pre-PLUVICTO® 2L and 3L mCRPC patients.

Vir Biotechnology Stock Soars on Promising Hepatitis and Oncology Data

6 months ago

• Vir Biotechnology's stock surged following positive Phase 2 data for its hepatitis programs, particularly tobevibart and elebsiran, showcasing potential in treating chronic hepatitis delta and B infections. • The company's strategic focus on HDV, HBV, and T-cell engagers, including a licensing deal with Sanofi, has bolstered investor confidence and analyst ratings. • Recent clinical trials demonstrated significant rates of hepatitis B surface antigen loss and anti-HBs seroconversion, suggesting potential for functional cures in chronic hepatitis B. • Vir Biotechnology plans to initiate a registrational program for its hepatitis delta virus treatment in 2025, signaling its commitment to advancing its therapeutic offerings.

Robust Clinical Trial Pipeline Fuels Hope for Renal and Breast Cancer Advances

8 months ago

• The renal cancer clinical trial pipeline is robust, with over 70 companies developing more than 75 therapies, including novel immunotherapies and targeted agents. • Breast cancer research is also thriving, with over 100 companies exploring 120+ new drugs, such as antibody-drug conjugates and PARP inhibitors, in clinical trials. • Recent FDA actions, including Fast Track and Breakthrough Therapy designations, highlight the potential of emerging therapies for both renal and breast cancer. • Advances in diagnostics, such as PET imaging agents for clear cell renal cell carcinoma, are also contributing to improved management of these diseases.